Enfusion, Inc.
Enfusion, Inc. (ENFN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
enfn · stock forecast · 8 analysts (3M) · FMP · updated Nov 18, 2025
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Hold
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $10.76
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $10.69 | ↓ 0.62% |
1-day model range: $10.67–$10.72. Peak: $10.72 (-0.62%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $11 | +0.8% |
| 2028 | $11 | +1.3% |
| 2029 | $11 | +1.5% |
| 2030 | $11 | +1.6% |
| 2031 | — | +1.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ENFN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-01-13 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2024-12-23 | Piper Sandler | Maintains | Neutral→Neutral |
| 2024-12-18 | Stifel | Maintains | Buy→Buy |
| 2024-03-13 | B of A Securities | Maintains | Underperform→Underperform |
| 2024-02-28 | Goldman Sachs | Downgrade ↓ | Neutral→Sell |
| 2024-01-30 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2023-12-20 | Piper Sandler | Maintains | Neutral→Neutral |
| 2023-08-09 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2023-08-09 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2023-08-08 | Morgan Stanley | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Enfusion, Inc. (ENFN) stock. Of the recent 49 rating actions, 2 were upgrades and 7 were downgrades. 8 analysts currently cover ENFN.
Analyst Recommendation Trends
ENFN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$188M
↓ 20.6% YoY
Revenue Next Year
$203M
↑ 7.7% YoY
EPS This Year
$0.04
EPS Next Year
$0.21
↑ 498.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast ENFN EPS of $0.04 for the current fiscal year, based on estimates from 4 analysts. The ENFN revenue forecast is $188M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ENFN stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ENFN price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The ENFN short-term stock prediction for tomorrow is $10.69 (-0.62%). The ENFN stock price prediction for 2027 estimates an average of $11. The ENFN stock prediction for 2030 projects a range of $11–$11.
Enfusion, Inc. trades on NYSE under the ticker ENFN. The ENFN stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 25% of covering analysts.
Frequently asked questions
ENFN forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month ENFN price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $10.76.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.